News
FDA kicks off review of Takeda's narcolepsy hopeful
The FDA has started a priority review of Takeda's oveporexton for sleep disorder narcolepsy, setting up a decision in the third quarter of the year.
News
AstraZeneca raises guidance on stellar cancer drugs growth
AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.
News
Dismay as FDA blocks Regenxbio's Hunter syndrome therapy
The FDA said it needs more information before it can approve Regenxbio's gene therapy for Hunter syndrome, in a devastating decision for patients.
News
Lupin settles Myrbetriq patent spat with Astellas for $90m
Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.
News
Novo Nordisk rises as Hims & Hers backs down on oral GLP-1
Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
